X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of atopic dermatitis. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface and to other bacteria.
Lead Product(s): Gentamicin Sulfate
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. Bacterial biofilms are specialized communities consisting of bacteria adhered to a surface and to other bacteria.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 03, 2023
Details:
BioLexa (gentamicin) is a patented, proprietary antimicrobial topical formulation being developed for treatment of diseases mediated by Staphylococcal biofilms. The BioLexa formulation is optimized to prevent Staphylococcal biofilm formation.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 29, 2022
Details:
Receiving clearance for Cohort 2 is the next critical milestone in the Phase 1b clinical trial in Australia. Hoth's atopic dermatitis solution, BioLexa, represents a significant global opportunity and looks forward to advancing the treatment through the clinic.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
BioLexa is patented, proprietary antimicrobial topical formulation against diseases mediated by Staphylococcal biofilms. BioLexa formulation is optimized to prevent Staphylococcal biofilm formation, keeping bacteria in more susceptible state to antimicrobial therapy.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2021
Details:
The first in human clinical trial is randomized, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, in adult and adolescent patients with mild to moderate AD.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
Details:
The Company currently intends to use the net proceeds from the private placement for further development of Hoth's product candidates including lead drug BioLexa and for working capital and general corporate purposes.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 08, 2021
Details:
Hoth Therapeutics has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Details:
Following the successful completion of the Phase 1b trial, the Company intends to conduct a Phase 2 trial with adult and adolescent patients to continue clinical investigation of the efficacy of BioLexa Lotion for treatment of mild to moderate atopic dermatitis.
Lead Product(s): Gentamicin Sulfate,Pentetic Acid
Therapeutic Area: Dermatology Product Name: BioLexa
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
